Management of cancer-associated thromboembolism in vulnerable population

Laporte, Silvy; Benhamou, Ygal; Bertoletti, Laurent; Frère, Corinne; Hanon, Olivier; Couturaud, Francis; Moustafa, Farès; Mismetti, Patrick; Sanchez, Olivier; Mahé, Isabelle

doi:10.1016/j.acvd.2023.11.009

Cited by 8 publications

(1 citation statement)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our review, we excluded studies reporting thromboembolic events in patients using antipsychotics who also suffered from end-stage diseases; these were omitted due to the inherently higher thrombotic risk in these populations, which could have confounded our assessment [3][4][5]. Additionally, we excluded studies focusing on postoperative patients, as the increased baseline risk for thromboembolism associated with surgery could potentially skew our analysis of antipsychotic-related risks [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 and Antipsychotic Therapy: Unraveling the Thrombosis Risk

Dho-Nagy,

Brassai,

Lechsner

et al. 2024

IJMS

View full text Add to dashboard Cite

In the context of the COVID-19 pandemic, this study investigates the potential correlation between the increased use of antipsychotic medications and the rising incidence of venous thromboembolism (VTE). As psychiatric disorders surged, the consequential escalation in antipsychotic drug use raised concerns about thrombotic risks. We conducted a comprehensive literature review using PubMed, focusing on articles that intersected COVID-19, antipsychotic medication, and thrombosis. This approach allowed for a nuanced examination of the historical and recent data on antipsychotic drugs and their association with thrombotic events. Our findings reveal a notable link between the use of antipsychotic medications, particularly second-generation antipsychotics, and an increased risk of VTE, including pulmonary embolism and deep vein thrombosis. This association was evident, despite variations in study designs and populations. The study underscores the need for cautious medication management in psychiatric care, especially during pandemic conditions like COVID-19, to mitigate thrombotic risks. It advocates a personalized approach to prescribing antipsychotics, considering individual patient factors and comorbidities, to balance the benefits against potential thrombotic complications.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 and Antipsychotic Therapy: Unraveling the Thrombosis Risk

Dho-Nagy,

Brassai,

Lechsner

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Venous thrombosis and obesity: from clinical needs to therapeutic challenges

La Rosa,

Montecucco,

Liberale

et al. 2024

Intern Emerg Med

View full text Add to dashboard Cite

Weight bias and stigma have limited the awareness of the systemic consequences related to obesity. As the narrative evolves, obesity is emerging as a driver and enhancer of many pathological conditions. Among these, the risk of venous thromboembolism (VTE) is a critical concern linked to obesity, ranking as the third most common cardiovascular condition. Obesity is recognized as a multifactorial risk factor for VTE, influenced by genetic, demographic, behavioral, and socio-economic conditions. Despite established links, the exact incidence of obesity related VTE in the general population remains largely unknown. The complexity of distinguishing between provoked and unprovoked VTE, coupled with gaps in obesity definition and assessment still complicates a tailored risk assessment of VTE risk. Obesity reactivity, hypercoagulability, and endothelial dysfunction are driven by the so-called ‘adiposopathy’. This state of chronic inflammation and metabolic disturbance amplifies thrombin generation and alters endothelial function, promoting a pro-thrombotic environment. Additionally, the inflammation-induced clot formation—also referred to as ‘immunothrombosis’ further exacerbates VTE risk in people living with obesity. Furthermore, current evidence highlights significant gaps in the management of obesity related VTE, particularly concerning prophylaxis and treatment efficacy of anticoagulants in people living with obesity. This review underscores the need for tailored therapeutic approaches and well-designed clinical trials to address the unique challenges posed by obesity in VTE prevention and management. Advanced research and innovative strategies are imperative to improve outcomes and reduce the burden of VTE in people living with obesity.

show abstract